LC/MS, LC/MS/MS, LC/TOF, LC/HRMS, 2D-LC
IndustriesPharma & Biopharma
ManufacturerAgilent Technologies
Impurity Analysis of GLP-1 Peptide Retatrutide — Executive Summary
Significance of the topic
Characterization of product-related impurities is a critical requirement in development and manufacturing of peptide therapeutics. GLP-1 receptor agonists such as retatrutide are structurally complex peptides for which closely related sequence variants, truncations, insertions, and chemical byproducts can co-elute with the main product or appear at very low abundance. Reliable identification and characterization of these species is essential for product quality, regulatory compliance, and understanding synthetic or degradation pathways. Combining chromatographic selectivity optimized for UV-based release or QC methods with MS-based accurate-mass and sequence analysis addresses the competing needs of chromatography and mass spectrometry in peptide impurity workflows.
Objectives and study overview
This application study demonstrates an integrated 2D-LC/MS workflow that preserves a TFA-optimized first-dimension LC separation (maximizing chromatographic resolution for retatrutide and its impurities) while enabling MS-compatible, accurate-mass detection by transferring selected fractions online into a formic acid (FA)-based second-dimension LC prior to Agilent 6230C TOF MS analysis. Key aims were to (1) compare chromatographic selectivity of TFA versus FA on a peptide-specialized stationary phase; (2) show online multiple heart-cutting transfer of selected 1D peaks to a short 2D MS-compatible method; and (3) demonstrate intact-peptide mass assignment and candidate impurity identification using MassHunter BioConfirm software.
Methodology and instrumentation used
Instrumentation and modules used in the study:
- Agilent 1290 Infinity III bio 2D-LC platform composed of: multisampler with thermostat (G7137A), multicolumn thermostat (G7116B), diode array detector (G7117B) with Max-Light cell, 1260 Infinity III bio flexible pump (G7131C), 1290 Infinity III high-speed pump (G7132A), valve drive (G1170A) with InfinityLab 2D-LC ASM Valve (G5643B), two additional valve drives (G1170A) with InfinityLab bio multiple heart-cutting valves (G5642-64000) equipped with 40 µL loops.
- Agilent 6230C Time-of-Flight (TOF) LC/MS system with Agilent Jet Stream (AJS) electrospray source.
Sample and general LC/MS method details:
- Analyte: Retatrutide standard reconstituted at 2 mg/mL in water.
- 1D (TFA-optimized) column: Agilent Altura Peptide Plus, 2.1 × 150 mm, 2.7 µm; mobile phases 0.1% TFA in water (A) and 0.1% TFA in ACN (B); column temp 80 °C; flow 0.4 mL/min; UV detection at 220 nm. This TFA-based method was used to maximize resolution of product and closely related impurities.
- 2D (MS-compatible) column: Agilent Altura Peptide Plus, 2.1 × 50 mm, 2.7 µm; mobile phases 0.1% FA in water (A) and 0.1% FA in ACN (B); short 3-minute gradient to provide rapid, MS-friendly separation after heart-cutting.
- 2D-LC mode: time-based multiple heart-cutting (six cuts across the region containing main product and impurities). Multiple cuts across the major peak were used to reduce load and avoid MS detector saturation.
- MS settings (representative): AJS source, gas temp ~325 °C, sheath gas temp ~350 °C, capillary ~3500 V, nozzle 400 V, fragmentor 175 V, skimmer 45 V; acquisition m/z 100–3200, acquisition rate ~5 spectra/s.
- Data processing: Agilent MassHunter acquisition, MassHunter Qualitative Analysis, and MassHunter BioConfirm (version 14.1). The BioConfirm intact-peptide workflows used included the MS-based Target Plus Impurities (TPI) deconvolution/impurity screening workflow; file-splitting utility automatically separated 2D-LC cuts for individual analysis.
Main results and discussion
Chromatographic comparison (TFA vs FA):
- Using identical gradient conditions on the Altura Peptide Plus stationary phase, the 0.1% TFA 1D method provided superior resolution of retatrutide impurities (three impurity peaks, P1–P3) from the main product peak (M). P1–P3 were baseline resolved from M using TFA, whereas P2 coeluted with M under FA-based conditions. The Altura stationary phase offers additional charged-surface selectivity that accentuates differences between ion-pairing modifiers.
2D-LC multiple heart-cutting performance:
- Selected heart-cuts (six windows) transferred targeted 1D fractions online into a short FA-based 2D method prior to TOF detection. Low-abundance impurities (relative UV area: P1 0.89%, P2 1.64%, P3 2.90%; main product M 94.58%) produced sufficient MS signal after transfer.
- Multiple cuts across the high-abundance main product peak distributed sample load across several injections to avoid MS saturation while maintaining adequate signal for low-level species.
MS analysis and sequence assignment:
- MS1 deconvolution with BioConfirm produced monoisotopic mass for retatrutide of 4728.4635 Da, matching theoretical mass 4728.4718 Da with ≈–1.8 ppm mass error, and displayed predicted isotopic distributions matched to experimental clusters.
- The TPI MS1 workflow returned candidate sequence-level assignments for five impurity species across the cuts: Del(11–12 SI), Del(12 I), Del(31 P), Del(35–36 AP), and Ins(10 Y). These MS1-based assignments relied on accurate-mass and isotopic pattern matching; targeted MS/MS (e.g., BioConfirm PI workflow) would be required to confirm residue-level positions unambiguously.
Overall interpretation:
- The integrated strategy preserves the chromatographic selectivity advantage of TFA in 1D while enabling MS-compatible detection and intact-peptide deconvolution via a short FA 2D method, avoiding method redevelopment or offline fraction collection.
- MS1-based intact-peptide screening is effective for candidate impurity identification but should be complemented by MS/MS for full sequence confirmation, particularly for isobaric residues or positional ambiguity.
Benefits and practical applications
The presented workflow offers multiple practical advantages for peptide impurity analysis in development and QC contexts:
- Method preservation: allows laboratories to retain validated TFA‑based UV separation methods while adding targeted MS characterization without changing 1D conditions.
- Targeted sensitivity: multiple heart-cutting concentrates MS effort on peaks of interest, improving detection of low-abundance impurities without large-volume fraction collection.
- Operational efficiency: online heart-cutting eliminates offline manual fraction collection and re-analysis, speeding characterization workflows.
- Intact-peptide capability: BioConfirm supports deconvolution and handling of nonnatural amino acids and long side-chain modifications, making the approach applicable to modern modified peptides.
Future trends and potential applications
Opportunities to extend and enhance this approach include:
- Routine coupling with MS/MS-based intact-peptide PI workflows to provide residue-level confirmation of candidate impurities identified by MS1 screening.
- Adoption of higher-resolution or higher-sensitivity mass analyzers and advanced ion sources to push detection limits for trace-level impurities.
- Expanded automation and software integration for automated cut-definition, file splitting, batch-level impurity screening, and report generation for regulatory submissions.
- Application to other complex peptide and peptidomimetic therapeutics, including ADC payload peptides, cyclic peptides, and peptides with multiple noncanonical residues.
- Use in comparability, forced-degradation studies, and in-process control where preserving established chromatographic selectivity is important.
Conclusion
The study demonstrates an effective 2D-LC/MS strategy that combines a TFA-optimized first-dimension LC for maximal chromatographic separation with an FA-based, MS-compatible second dimension to enable accurate-mass intact-peptide detection and preliminary sequence assignment. Multiple heart-cutting permits targeted transfer of low-level impurities and control of analyte load to the MS, enabling confident MS1 deconvolution of the main product and related impurities. The workflow delivers practical benefits for impurity characterization of complex therapeutic peptides while keeping established LC/UV methods intact and streamlining online MS-based investigation.
References
- Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514–526. DOI: 10.1056/NEJMoa2301972.
- Ryu C.-Y. Confirmation of Peptide-Related Impurity Intact Mass Using Agilent 1290 Infinity II Bio 2D-LC and InfinityLab LC/MSD XT. Agilent Technologies application note. Publication 5994-7654EN. 2024.
- Agilent Technologies. Take a Giant Step Forward in Biomolecule Characterization. Brochure. Publication 5991-8466EN. 2026.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.